These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 23472883)

  • 1. The renal endothelium in diabetic nephropathy.
    Eleftheriadis T; Antoniadi G; Pissas G; Liakopoulos V; Stefanidis I
    Ren Fail; 2013; 35(4):592-9. PubMed ID: 23472883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy.
    Ziyadeh FN; Wolf G
    Curr Diabetes Rev; 2008 Feb; 4(1):39-45. PubMed ID: 18220694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Local VEGF activity but not VEGF expression is tightly regulated during diabetic nephropathy in man.
    Hohenstein B; Hausknecht B; Boehmer K; Riess R; Brekken RA; Hugo CP
    Kidney Int; 2006 May; 69(9):1654-61. PubMed ID: 16541023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationships among microalbuminuria, insulin resistance and renal-cardiac complications in insulin dependent and non insulin dependent diabetes.
    Nosadini R; Brocco E
    Exp Clin Endocrinol Diabetes; 1997; 105 Suppl 2():1-7. PubMed ID: 9288531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy.
    Nakagawa T; Sato W; Glushakova O; Heinig M; Clarke T; Campbell-Thompson M; Yuzawa Y; Atkinson MA; Johnson RJ; Croker B
    J Am Soc Nephrol; 2007 Feb; 18(2):539-50. PubMed ID: 17202420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients.
    Pistrosch F; Herbrig K; Kindel B; Passauer J; Fischer S; Gross P
    Diabetes; 2005 Jul; 54(7):2206-11. PubMed ID: 15983223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased expression of endothelial cell nitric oxide synthase (ecNOS) in afferent and glomerular endothelial cells is involved in glomerular hyperfiltration of diabetic nephropathy.
    Sugimoto H; Shikata K; Matsuda M; Kushiro M; Hayashi Y; Hiragushi K; Wada J; Makino H
    Diabetologia; 1998 Dec; 41(12):1426-34. PubMed ID: 9867209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The endothelium in diabetic nephropathy.
    Advani A; Gilbert RE
    Semin Nephrol; 2012 Mar; 32(2):199-207. PubMed ID: 22617769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Podocyte detachment and reduced glomerular capillary endothelial fenestration in human type 1 diabetic nephropathy.
    Toyoda M; Najafian B; Kim Y; Caramori ML; Mauer M
    Diabetes; 2007 Aug; 56(8):2155-60. PubMed ID: 17536064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nephrin and endothelial injury.
    Hauser PV; Collino F; Bussolati B; Camussi G
    Curr Opin Nephrol Hypertens; 2009 Jan; 18(1):3-8. PubMed ID: 19077682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glomerular dysfunction in diabetic nephropathy.
    Zucchelli P; Zuccalà A; Sturani A
    Postgrad Med J; 1988; 64 Suppl 3():22-30; discussion 48-9. PubMed ID: 3074295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular endothelial dysfunction: a tug of war in diabetic nephropathy?
    Balakumar P; Chakkarwar VA; Krishan P; Singh M
    Biomed Pharmacother; 2009 Mar; 63(3):171-9. PubMed ID: 18823739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What is the mechanism of microalbuminuria in diabetes: a role for the glomerular endothelium?
    Satchell SC; Tooke JE
    Diabetologia; 2008 May; 51(5):714-25. PubMed ID: 18347777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of NO-synthase expression and clinical risk factors in human diabetic nephropathy.
    Hohenstein B; Hugo CP; Hausknecht B; Boehmer KP; Riess RH; Schmieder RE
    Nephrol Dial Transplant; 2008 Apr; 23(4):1346-54. PubMed ID: 18065828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathogenesis of diabetic nephropathy.
    Raptis AE; Viberti G
    Exp Clin Endocrinol Diabetes; 2001; 109 Suppl 2():S424-37. PubMed ID: 11460589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis.
    Isermann B; Vinnikov IA; Madhusudhan T; Herzog S; Kashif M; Blautzik J; Corat MA; Zeier M; Blessing E; Oh J; Gerlitz B; Berg DT; Grinnell BW; Chavakis T; Esmon CT; Weiler H; Bierhaus A; Nawroth PP
    Nat Med; 2007 Nov; 13(11):1349-58. PubMed ID: 17982464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complete remission of diabetic nephropathy in a type 1 diabetic patient with near-nephrotic range proteinuria and reduced renal function.
    Haraguchi K; Hara S; Ubara Y; Tanaka S; Nukui I; Shimura H; Ohashi K; Kobayashi T
    Diabetes Res Clin Pract; 2009 Mar; 83(3):295-9. PubMed ID: 19162360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of high glucose and transforming growth factor-β on bioenergetic profiles in podocytes.
    Stieger N; Worthmann K; Teng B; Engeli S; Das AM; Haller H; Schiffer M
    Metabolism; 2012 Aug; 61(8):1073-86. PubMed ID: 22365040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects on protein kinase C-beta inhibition on glomerular vascular endothelial growth factor expression and endothelial cells in advanced experimental diabetic nephropathy.
    Kelly DJ; Buck D; Cox AJ; Zhang Y; Gilbert RE
    Am J Physiol Renal Physiol; 2007 Aug; 293(2):F565-74. PubMed ID: 17522264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of vascular endothelial growth factor (VEGF) does not affect early renal changes in a rat model of lean type 2 diabetes.
    Schrijvers BF; De Vriese AS; Tilton RG; Van de Voorde J; Denner L; Lameire NH; Flyvbjerg A
    Horm Metab Res; 2005 Jan; 37(1):21-5. PubMed ID: 15702434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.